mRNA Platform Market by mRNA Type (Nucleoside-Modified mRNA, Self-Amplifying mRNA, Unmodified mRNA), Indication (Autoimmune Diseases, Cancer, Infectious Diseases), Application, End-User - Global Forecast 2024-2030

mRNA Platform Market by mRNA Type (Nucleoside-Modified mRNA, Self-Amplifying mRNA, Unmodified mRNA), Indication (Autoimmune Diseases, Cancer, Infectious Diseases), Application, End-User - Global Forecast 2024-2030

The mRNA Platform Market size was estimated at USD 13.52 billion in 2023 and expected to reach USD 16.33 billion in 2024, at a CAGR 21.44% to reach USD 52.71 billion by 2030.

The mRNA (messenger RNA) platform is a novel approach in the field of medicine and biotechnology, primarily utilized for the development of vaccines and therapeutics. mRNA serves as a molecular intermediary between the DNA in cells and the proteins that are essential for various bodily functions. The mRNA platform leverages synthetic mRNA to instruct cells to produce specific proteins that can trigger an immune response or stimulate cell repair without altering the cell's DNA. The ability of mRNA platforms to accelerate the development and production of vaccines and the rising global need to effectively and quickly produce vaccines has driven the need for mRNA platforms. mRNA therapies can be tailored to fight a wide array of diseases, from infectious diseases to cancer, by simply modifying the mRNA sequence the vaccines carry. This versatility opens up new avenues in personalized medicine and treatments for various conditions. However, mRNA vaccines and therapeutics require ultra-cold storage to remain stable, presenting logistical challenges in distribution, particularly in regions with limited infrastructure. Efficiently delivering mRNA into cells without degradation is a considerable hurdle. Researchers are continuously working on finding and improving lipid nanoparticles and other delivery methods to protect the mRNA until it reaches the target cells. Beyond preventive vaccines, mRNA technology is being explored for therapeutic applications, including cancer treatment, genetic disorders, and autoimmune diseases.

Regional Insights

The Americas, particularly the United States and Canada, present a mature landscape for the mRNA platform, driven by the high healthcare expenditure, sophisticated healthcare infrastructure, and a strong focus on research and innovation. The Americas region is characterized by the presence of several biotechnology and pharmaceutical companies that frequently invest in R&D programs to improve the safety, efficiency, and performance of mRNA platforms. EU countries lead in regulatory frameworks supporting mRNA research and product approvals. Nations such as the U.K., Germany, and France have strong biotech sectors that are propelled by collaborative efforts between governments, academia, and private sectors. The European Medicine Agency (EMA) plays a pivotal role in facilitating the swift approval of mRNA-based treatments. APAC region is a rapidly evolving landscape for mRNA platform technologies driven by China, Japan, and India. The region's significant population base presents a vast need for vaccines and therapeutic treatments, including mRNA platforms. Government support for improving the healthcare infrastructure notably and a growing awareness of advanced treatment modalities present significant opportunities for the expansion of mRNA platforms. APAC's strategic position as a manufacturing hub for vaccines and drug therapeutics also serves to create a conducive framework for driving the adoption of mRNA platforms.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the mRNA Platform Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

• Surge in demand of therapies and vaccines due to the infectious diseases
• Need to reduce vaccine development and commercialization timeline

Market Restraints

• Complexity in optimising manufacturing and commercial pathways

Market Opportunities

• Increased market capitalization and public funding
• mRNA technology optimization on development of on-demand vaccines

Market Challenges

• High regulatory risk and hurdles in supply logistics

Market Segmentation Analysis

• mRNA Type: Ability of nucleoside-modified mRNA to balance immune response efficacy with reduced side effects and offer enhanced stability
• End-User: Extensive involvement of pharmaceutical companies in the marketing and authorization of mRNA platforms

Market Disruption Analysis

• Porter’s Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the mRNA Platform Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the mRNA Platform Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

VBI Vaccines Inc.'s Groundbreaking Advancement in mRNA Vaccine Technology with Government of Canada Support

VBI Vaccines Inc. expanded its collaborative efforts with the Canadian Government, dedicating an additional CAD 28 million towards the advancement of VBI's innovative MLE platform. This next-gen initiative enhances VBI's virus-like particle (eVLP) vaccine technology through the use of messenger RNA (mRNA), showing promise in preclinical studies with strong immune responses. The investment also supports the development of stable cell lines tailored for rapid adaptation to various viral targets and optimizes manufacturing processes for better efficacy. This collaboration primarily focuses on the platform's development and includes efforts toward a comprehensive solution for future epidemic and pandemic preparedness, marking a significant stride in vaccine technology and public health security.

Elevating the Future of Healthcare: The Pioneering Alliance for mRNA Medicines

In response to the unparalleled success of mRNA technology during the COVID-19 pandemic, 31 leading entities spanning biotechnology, biopharma, life sciences, and academia have joined forces to establish the Alliance for mRNA Medicines (AMM). As mRNA technology has shown vast promise in disease prevention and treatment, including potential applications in cancer therapy, AMM aims to propel the evolution of mRNA medicine. By fostering collaboration among industry pioneers, innovators, and other vital stakeholders, AMM is dedicated to advancing scientific standards, public policies, and educational efforts to support future breakthroughs.

Sensible Biotechnologies and Ginkgo Bioworks Forge Strategic Alliance for Revolutionizing mRNA Production

In a significant stride towards advancing mRNA technology, Sensible Biotechnologies collaborated with Ginkgo Bioworks and aims to pioneer an in vivo microbial mRNA manufacturing platform, marking a departure from the conventional in vitro transcription (IVT) methods. Traditional IVT methods, although widely used for vaccine and therapeutic mRNA production, are hampered by scalability limitations, necessitating costly purification steps to remove harmful byproducts. The innovative in vivo approach proposed by Sensible and Ginkgo seeks to dramatically increase production capacity to over 100,000L and enhance mRNA quality, enabling the manufacture of longer mRNA molecules and broadening the spectrum of possible mRNA-based treatments.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the mRNA Platform Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the mRNA Platform Market, highlighting leading vendors and their innovative profiles. These include Accanis Biotech F&E GmbH & Co KG, Aldevron, LLC by Danaher Corporation, Arcturus Therapeutics, Inc., Argos Therapeutics, Inc., AstraZeneca plc, Avectas Limited, BioNTech SE, Catalent, Inc., CRISPR Therapeutics AG, CureVac N.V., Daiichi Sankyo, Dicerna Pharmaceuticals, Inc by Novo Nordisk A/S, eTheRNA, ethris GmbH, Gritstone bio, In-Cell-Art, Merck & Co., Inc., Moderna, Inc., Pfizer Inc., Precision BioSciences, Inc., Regulus Therapeutics Inc., Sangamo Therapeutics, Inc., Sanofi S.A., Tiba Biotech LLC, and Verve Therapeutics.

Market Segmentation & Coverage

This research report categorizes the mRNA Platform Market to forecast the revenues and analyze trends in each of the following sub-markets:

mRNA Type

• Nucleoside-Modified mRNA
• Self-Amplifying mRNA
• Unmodified mRNA
• Indication
• Autoimmune Diseases
• Cancer
• Personalized Treatment
• Single Cancer Focussed
• Infectious Diseases
• Rare Diseases
• Respiratory Diseases

Application

• Therapeutics
• Vaccines
• End-User
• Hospitals & Clinics
• Pharmaceutical Companies
• Research & Academic Institutiions

Region

• Americas
• Argentina
• Brazil
• Canada
• Mexico
• United States
• California
• Florida
• Illinois
• New York
• Ohio
• Pennsylvania
• Texas
• Asia-Pacific
• Australia
• China
• India
• Indonesia
• Japan
• Malaysia
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• Europe, Middle East & Africa
• Denmark
• Egypt
• Finland
• France
• Germany
• Israel
• Italy
• Netherlands
• Nigeria
• Norway
• Poland
• Qatar
• Russia
• Saudi Arabia
• South Africa
• Spain
• Sweden
• Switzerland
• Turkey
• United Arab Emirates
• United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year